Bode C, Peter K, Moser M, Smalling R W, Weaver W D
Medizinische Klinik III (Kardiologie), Universitat Heidelberg, Germany.
Eur Heart J. 1997 Dec;18 Suppl F:F17-21. doi: 10.1093/eurheartj/18.suppl_f.17.
Thrombolysis has become an accepted form of therapy for acute myocardial infarction. As demonstrated in the Global Utilization of Streptokinase and t-PA for Occluded Arteries trial, early, complete and sustained patency of the infarct-related coronary artery is correlated with reduced mortality. However, current thrombolytic regimens are able to achieve such patency within 90 min in only 81% of cases. To improve the risk/benefit ratio of thrombolytic therapy, newer agents such as reteplase have been developed to establish more rapid, more complete and more stable coronary artery patency, thus reducing mortality. This report summarizes the pharmacological properties of reteplase. It also summarizes the findings from various animal and clinical studies in which reteplase was compared with alteplase and streptokinase and the findings from animal and clinical studies evaluating infusion, single-bolus, double-bolus, doses of reteplase.
溶栓治疗已成为急性心肌梗死公认的治疗方式。正如在“链激酶及组织型纤溶酶原激活剂治疗闭塞动脉的全球应用”试验中所证明的那样，梗死相关冠状动脉的早期、完全且持续开通与死亡率降低相关。然而，目前的溶栓方案仅在81%的病例中能够在90分钟内实现这种开通。为了改善溶栓治疗的风险/效益比，已研发出如瑞替普酶等新型药物，以实现更快速、更完全且更稳定的冠状动脉开通，从而降低死亡率。本报告总结了瑞替普酶的药理学特性。它还总结了各种动物和临床研究的结果，这些研究将瑞替普酶与阿替普酶和链激酶进行了比较，以及评估瑞替普酶输注、单次推注、两次推注剂量的动物和临床研究结果。
